Fred Hutch Cancer Center

MINUTES OF THE FRED HUTCHINSON CANCER CENTER
INSTITUTIONAL BIOSAFETY COMMITTEE

August 21st, 2025 IBC Special Meeting, 11:00 am, MS Teams

ATTENDANCE

MEMBERS

Present	*Absent*	
☒	☐	Kevin Barry PhD, Public Health Sciences, *Member*
☒	☐	Elizabeth Cromwell, PDX Program Lead, *Member*
☒	☐	Bernadeta Dadonaite PhD, Staff Scientist, Basic Sciences, *Member*
☐	☒	Neelendu Dey MD, PhD, Clinical Research Division, *Member*
☒	☐	Michael Emerman PhD, Human Biology, *Member*
☐	☒	Marian Esvelt DVM, Associate Director, Comparative Medicine, *Member*
☒	☐	Taran Gujral PhD, Human Biology, *Member*
☒	☐	Tony Han, BSL-3/ABSL-3 Facility Manager, *Member*
☒	☐	Keith Jerome MD, PhD, Vaccine and Infectious Disease, *Chairperson*
☒	☐	Michelle Kom-Gochnour MN, RN, COHN-S, *Community Member*
☒	☐	John McNevin MSc, Program Manager, Vaccine and Infectious Disease, *Member*
☒	☐	Jacqui Murray-Wijelath PhD, *Community Member*
☒	☐	Susan Parazzoli MS, RBP, Biosafety Officer, *Member*
☐	☒	Stefan Radtke PhD, Staff Scientist, Translational Science & Therapeutics, *Member*
☐	☒	Joshua Schiffer MD, MSc, Clinical Research, *Member*
☒	☐	Susan Strenk, Research Technician III, Vaccine and Infectious Disease, *Member*
☒	☐	Andrea Towlerton, HCRI Lab Director, *Member*
☐	☒	Allison Zelikoff MN, RN, COHN-S, Occupational Nurse Manager, *Member*

NON-MEMBERS

Jake White, Assistant Biosafety Officer, Environmental Health & Safety
Cindy Wladyka, EH&S Specialist for Biosafety, Environmental Health & Safety

VISITORS

None

Dr. Jerome, Chairperson, called the meeting to order at 11:02 am.

I. ANNOUNCEMENTS AND UPDATES

- None

II. REMINDER FOR CONFLICT OF INTEREST

The chair reminded the committee that the NIH Guidelines, Section IV-B-2-a-(4) states: “No member of an Institutional Biosafety Committee may be involved (except to provide information requested by the

Institutional Biosafety Committee) in the review or approval of a project in which he/she has been or expects to be engaged or has a direct financial interest."

III. MINUTES

None

IV. REVIEW OF ACTION ITEMS

None

V. NEW BUSINESS

HVTN TRIAL UPDATES

None

CATEGORY "A" IBC REVIEWS

Principal Investigator:	*EMUA Type:*	*EMUA Number & Title:*	*NIH Sections:*
Bloom	Renewal	E325.3 Bloom Lab at FHCC	III-D-1, III-D-2, III-D-3, III-D-7, III-E-1, III-F-1, III-F-2, III-F-3, III-F-4, III-F-5, III-F-8

Summary (including agents, manipulations, genes, hosts, proposed containment/biosafety levels):

- The overall goal of this work is to study viral evolution and the impact of mutations to viral proteins.
- Lab strains of E. coli for routine cloning will be handled at BSL-1
- Yeast strains for routine fungal culture and transformations will be handled at BSL-1
- Routine culturing of modified and un-modified human cell lines will be done at BSL-2.
- Gene targets include viral receptor proteins, cellular proteases, viral entry proteins, non-structural capsids of risk group 2 virus and reporters; modifications will be made using viral transduction and CRISPR-Cas 9 lipofectamine transfection at BSL-2
- Culturing and in-vitro experiments of lab-adapted risk group 2 viruses at BSL-2

Comments & Discussion:

Despite the complexity of the protocol, no concerns and everything is well explained. Proposed containment is appropriate for the work described.

Training & Facilities:	*Vote & Recusals:*
Facilities have been inspected and all findings resolved. Training is up-to-date and complete.	Approved (1 recusal)

Principal Investigator:	*EMUA Type:*	*EMUA Number & Title:*	*NIH Sections:*
Parkhurst	Renewal	E325.5 Parkhurst Lab at FHCC	III-D-4, II-E, III-F-1

Summary (including agents, manipulations, genes, hosts, proposed containment/biosafety levels):

- The Parkhurst lab is in Basic Sciences and tries to understand wound healing response and the biological basis of single-cell and tissue wound repair.
- Routine cloning in various lab strains of E.coli to purify Drosophila proteins- the proteins are then used for various in-vitro biochemical assays like actin binding and bundling.
- Culturing of various drosophila cell lines
- Use of wildtype and transgenic drosophila that they edit and create themselves
- The gene table lists various drosophila genes involved in wound repair processes. Some have human orthologs, none are involved in cancer
- For Gene delivery, the will use a number of cloning/expression plasmids and drosophila transformation vectors and yeast transformation vector.
- They will also generate fly knockouts and knockins using CRISPR. For the knockouts and knock ins, they will inject gRNA into embryos of flies that stably express Cas9 in the germline. The resulting progeny are crossed to a balancer chromosome to establish a fly line. The reason this isn't a gene drive is that the gRNAs are transiently expressed, and the chromosome with the Cas 9 insertion is removed in the F2 generation. The established lines are only stable for the deletion of interest.
- All the work described is to be performed at BSL-1.

Comments & Discussion:

No outstanding issues and recommend approval. Clarifications made appropriately addressed concerns from the previous meeting. Proposed containment is appropriate for the work described.

Training & Facilities:	***Vote & Recusals:***
Facilities have been inspected and all findings resolved. Training is up-to-date and complete.	Approved

Principal Investigator:	***EMUA Type:***	***EMUA Number & Title:***	***NIH Sections:***
Strong	Renewal	E325.6 Strong Lab at FHCC	III-D-3, III-E, III-F-1, III-F-2, III-F-8

Summary (including agents, manipulations, genes, hosts, proposed containment/biosafety levels):

- The lab conducts basic research studies on proteins involved in human immune responses to better understand their role in health and disease. They engineer novel forms of human immune proteins to develop agents for cancer immunotherapies.
- Lab strains of E. coli for routine cloning will be handled at BSL-1.
- Routine culturing of human cell lines will be done at BSL-2.
- Production and use of lentiviral vectors with non-oncogenic gene inserts for transduction of human cell lines will be done at BSL-2.
- FACS will be performed on transduced human cells with non-oncogenic inserts at BSL-2
- Gene targets include fluorescent reporters, proteases, peptide presentation and receptor ligands, risk group 2 viral proteins, tumor antigens and protein engineering scaffolding elements.

Comments & Discussion:

They are using a lot of genes so gene table lists a lot of classes of genes with examples. This method was recommended by the Biosafety team due to the large amount of genes used.
Proposed containment is appropriate for the work described.

Training & Facilities:	***Vote & Recusals:***

Facilities have been inspected and all findings resolved. Training is up-to-date and complete.	Approved

CATEGORY “B” IBC REVIEWS

Principal Investigator:	***EMUA Number:***	***NIH Sections:***	***Summary (including training and facilities):***
Peterson	E323.8	III-D-4, III-E-1	• Adding new lentiviral vector systems and production and use of lentivirus for transduction of human and non-human primate cell lines will be done at BSL-2. • No changes to personnel, facilities, or maximum approved containment level due to this amendment.
Batch Comments & Discussion:			
The Committee reviewed this work and confirmed the research is clearly described, the associated risks recognized, and appropriate biosafety practices implemented in accordance with institutional and regulatory standards.			
Batch Vote & Recusals/Abstentions:			
Approved (1 recusal)			

EMUA CLOSEOUTS

None

UPDATES/PROGRAM REVIEW

None

INCIDENTS, ACCIDENTS, AND PROBLEMS

None

VI. OTHER BUSINESS

None

Meeting adjourned at 11:25 AM.

DocuSigned by:
Keith Jerome
CB83B35EA7A9430...

Keith Jerome, MD PhD
Vaccine and Infectious Disease
Institutional Biosafety Committee Chairperson

DocuSigned by:
09CC928C5E494BB...

Susan Parazzoli MS, RBP
Biosafety Officer

cc: Dr. Thomas J. Lynch, President, and Director
Dr. Nicole (Niki) Robinson, Chief Administrative Officer